CD22 and systemic lupus erythematosus: Epratuzumab is a humanized IgG1 monoclonal antibody targeting CD22, which is used for the treatment of systemic lupus erythematosus (SLE) by inhibiting autophagy to block activation signals of the B-cell receptor and to promote the internalization of CD-22, thereby suppressing active B cells (113).